Zymeworks names Dr. Natalie Sacks to board

Zymeworks (NYSE:ZYME; TSX:ZYME) appointed Dr. Natalie Sacks, who has served as CMO of Aduro Biotech since Sept. 2016, to its board.

“Dr. Sacks brings a breadth of experience in immuno-oncology and will provide valuable insight to the board and our clinical team,” Ali Tehrani, president and CEO, said in a statement.

Dr. Sacks said that with ZW25 advancing through Phase 1 development, “this is an opportune time to join the board of directors and share my expertise with the company.”

Concurrent with the appointment, Zymeworks said Noel Hall is stepping down from the board.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.